Search Results - "Telep LE"

Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-A "knock-out" is yet to be delivered-Authors' reply.

Authors: Kim WR Telep LE Chokkalingam AP

Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 May; Vol. 55 (10), pp. 1344-1345.

Publication Type: Editorial; Comment

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

Letter: direct-acting anti-viral (DAA) therapy needs strong safety and efficacy check-authors' reply.

Authors: Singer AW Reddy KR Telep LE et al.

Source: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Jul; Vol. 48 (2), pp. 235-236.

Publication Type: Letter; Comment

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.

Authors: Fusco D Malenica I Günthard HF et al.

Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Nov 22; Vol. 79 (5), pp. 1182-1189.

Publication Type: Journal Article; Comparative Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.

Authors: Pan, Li-Xin Wang, Yi-Yang Li, Zhong-Hai et al.

Source: Trials. Dec2024, Vol. 25 Issue 1, p1-9. 9p.

Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection.

Authors: Chariyavilaskul, Pajaree Prompila, Nantaporn Wittayalertpanya, Supeecha et al.

Source: CTS: Clinical & Translational Science. Jul2024, Vol. 17 Issue 7, p1-12. 12p.

Role of hepatotropic viruses in promoting hepatocellular carcinoma-current knowledge and recent advances.

Authors: Starnawski P Nowak K Augustyn Z et al.

Source: Medical oncology (Northwood, London, England) [Med Oncol] 2025 Mar 17; Vol. 42 (4), pp. 111. Date of Electronic Publication: 2025 Mar 17.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

Development and validation of a nomogram for assessing hepatocellular carcinoma risk after SVR in hepatitis C patients with advanced fibrosis and cirrhosis.

Authors: Xu, Shanshan Qiu, Lixia Xu, Liang et al.

Source: Infectious Agents & Cancer. 4/25/2024, Vol. 19 Issue 1, p1-12. 12p.

Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis.

Authors: Ebel, Friederike Deterding, Katja Port, Kerstin et al.

Source: Alimentary Pharmacology & Therapeutics. Jan2020, Vol. 51 Issue 1, p194-195. 2p. 1 Graph.

The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis.

Authors: Mecci, Ali Jibran Kemos, Polychronis Leen, Clifford et al.

Source: Alimentary Pharmacology & Therapeutics. Jul2019, Vol. 50 Issue 2, p204-214. 11p. 1 Diagram, 3 Charts, 2 Graphs.

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma.

Authors: Lu, Haohao Zheng, Chuansheng Xiong, Bin et al.

Source: BMC Cancer. 3/13/2023, Vol. 23 Issue 1, p1-11. 11p.

Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.

Authors: Abdelhamed, Walaa El‐Kassas, Mohamed

Source: Journal of Viral Hepatitis. Feb2023, Vol. 30 Issue 2, p148-159. 12p.

Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory.

Authors: Li, Chenxi He, Wen‐Qiang

Source: Liver International. Oct2022, Vol. 42 Issue 10, p2299-2316. 18p. 7 Charts, 6 Graphs.

Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.

Authors: Takashi Kumada Hidenori Toyoda Satoshi Yasuda et al.

Source: Journal of Viral Hepatitis. Oct2022, Vol. 29 Issue 10, p919-929. 11p.

Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatment.

Authors: Kuwano, Akifumi Yada, Masayoshi Nagasawa, Shigehiro et al.

Source: Journal of Viral Hepatitis. Jan2022, Vol. 29 Issue 1, p35-42. 8p.

Long-Term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection.

Authors: Muzica, Cristina Maria Stanciu, Carol Cijevschi-Prelipcean, Cristina et al.

Source: Hepatitis Monthly. Jun2021, Vol. 21 Issue 6, p1-7. 7p.

Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents.

Authors: Ciancio, Alessia Ribaldone, Davide G. Dotta, Anna et al.

Source: Liver International. Feb2021, Vol. 41 Issue 2, p276-287. 12p. 6 Charts, 2 Graphs.

Hepatitis B Virus Treatment Gaps in the US.

Authors: Wong RJ Telep LE Wentworth CE et al.

Source: JAMA network open [JAMA Netw Open] 2025 Nov 03; Vol. 8 (11), pp. e2542744. Date of Electronic Publication: 2025 Nov 03.

Publication Type: Comparative Study; Journal Article

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir—a "knock‐out" is yet to be delivered.

Authors: Tonthat, Alexander V. Zhou, Kali

Source: Alimentary Pharmacology & Therapeutics. May2022, Vol. 55 Issue 10, p1342-1343. 2p.

Editorial: clinical impact of sofosbuvir renal toxicity—more light on the way.

Authors: Hernández‐Conde, Marta Calleja, José Luis

Source: Alimentary Pharmacology & Therapeutics. Apr2022, Vol. 55 Issue 8, p1052-1053. 2p.

Hyaluronic Acid act as a Non - Invasive Marker for Diagnosis of Liver Fibrosis in the Patients of Chronic Hepatitis C.

Authors: Akram, Muhammad Memon, Ali Raza Pushpa et al.

Source: Journal of Liaquat University of Medical & Health Sciences. Jul-Sep2018, Vol. 17 Issue 3, p161-164. 4p.